Please login to the form below

Not currently logged in
Email:
Password:

CLL

This page shows the latest CLL news and features for those working in and with pharma, biotech and healthcare.

Lilly drops Hanmi-partnered arthritis drug

Lilly drops Hanmi-partnered arthritis drug

The first BTK inhibitor to reach the market was Johnson &Johnson (J&J) and Pharmacyclics' Imbruvica (ibrutinib), but this has been introduced initially for blood cancers including chronic lymphocytic leukaemia (CLL)

Latest news

More from news
Approximately 10 fully matching, plus 76 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Asset acquisition - products. 121. † Eagle Pharmaceuticals/ Teva. EP-3102 - bendamustine hydrochloride rapid infusion product - CLL, indolent B-cell NHL. ... CLL, chronic lymphocytic leukaemia; NHL, indolent non-Hodgkin lymphoma.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Quest Diagnostics / Royalty Pharma. Purchase of royalty rights. Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3). ... Abbreviations. ImmTacs = Immune mobilising mTCR against cancer. CLL = chronic lymphocytic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics